Jurjen J Luykx, Frank Gerritse, Philippe C Habets, Christiaan H Vinkers
{"title":"The performance of ChatGPT in generating answers to clinical questions in psychiatry: a two-layer assessment.","authors":"Jurjen J Luykx, Frank Gerritse, Philippe C Habets, Christiaan H Vinkers","doi":"10.1002/wps.21145","DOIUrl":"10.1002/wps.21145","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"479-480"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503909/pdf/WPS-22-479.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10308187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Catatonia and its varieties: an update.","authors":"Andrew Francis, Charles Mormando","doi":"10.1002/wps.21119","DOIUrl":"10.1002/wps.21119","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"476-477"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503915/pdf/WPS-22-476.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10308179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mark van Ommeren, Sian Lewis, Edith Van't Hof, Kenneth Carswell
{"title":"Putting psychological interventions first in primary health care.","authors":"Mark van Ommeren, Sian Lewis, Edith Van't Hof, Kenneth Carswell","doi":"10.1002/wps.21114","DOIUrl":"10.1002/wps.21114","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"390-391"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10337472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recent developments pertaining to treatment-resistant depression: a 40-year perspective.","authors":"Michael E Thase","doi":"10.1002/wps.21134","DOIUrl":"10.1002/wps.21134","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"413-414"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503918/pdf/WPS-22-413.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10308177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Progress in understanding functional somatic symptoms and syndromes in light of the ICD-11 and DSM-5.","authors":"Francis Creed","doi":"10.1002/wps.21118","DOIUrl":"10.1002/wps.21118","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"474-475"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503926/pdf/WPS-22-474.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10308180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peter Szatmari, Christian Kieling, Andrea Raballo, Norbert Skokauskas, Bennett Leventhal
{"title":"Nurturing the next generation of clinician-scientists in child and adolescent psychiatry: recommendations from a WPA Presidential Task Force.","authors":"Peter Szatmari, Christian Kieling, Andrea Raballo, Norbert Skokauskas, Bennett Leventhal","doi":"10.1002/wps.21133","DOIUrl":"10.1002/wps.21133","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"493-494"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503920/pdf/WPS-22-493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10308183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David Mongan, Colm Healy, Emmet Power, Jonah F Byrne, Stan Zammit, Ian Kelleher, Mary Cannon, David R Cotter
{"title":"Thoughts of self-harm in late adolescence as a risk indicator for mental disorders in early adulthood.","authors":"David Mongan, Colm Healy, Emmet Power, Jonah F Byrne, Stan Zammit, Ian Kelleher, Mary Cannon, David R Cotter","doi":"10.1002/wps.21125","DOIUrl":"10.1002/wps.21125","url":null,"abstract":"","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 3","pages":"481-483"},"PeriodicalIF":73.3,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503913/pdf/WPS-22-481.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10337916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
271 other and which cluster with a target outcome, using replication to build confidence in an interpretation. Indeed, in the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP) study, it was the entire biomarker battery which went into defining the final characteristics of the experimental biomarkerdefined entities, which were called “psychosis biotypes”. These biotype constructs have provided research with an alternative to phenomenologically defined entities, as a stage in developing final disease cate gories. Moreover, it is the full biomarker battery which can be ap plied to distinguishing and understanding defined features of the illness, such as negative symptoms. BSNIP researchers have developed several individual studies, now ongoing, to test the clinical applicability of the above biotype constructs. One such study tests the hypothesis that biotype 1, with its low intrinsic EEG activity, is a biomarker which indicates responsiveness to clozapine; specifically, we test the hypothesis that increasing intrinsic EEG activity with clozapine in biotype 1 will correlate with symptomatological improvement, using the attractor network model. A second study, designed to predict treatment response in early psychosis, hypothesizes that the biotypes will define good (biotype 3), moderate (biotype 2) or poor (biotype 1) response to standard coordinated specialty care (CSC). In each of these examples, a doubleblind trial of the biomarker observation (now ongoing) is necessary, and its application can only be supported if this is done with rigorous design. There is no doubt that considerable hard work will have to go into the study of biomarkers in psychiatry before we are able to bring them to a clinically useful place. Yet, the validation of biomarkers, as reviewed in AbiDargham et al’s paper, can be so decisive for the future of our field that these stud ies need to be conducted. Costs have to be born. Yes, wisely; but urgently.
{"title":"The curse and opportunity of heterogeneity in the pursuit of psychiatric biomarkers.","authors":"Lianne Schmaal","doi":"10.1002/wps.21085","DOIUrl":"https://doi.org/10.1002/wps.21085","url":null,"abstract":"271 other and which cluster with a target outcome, using replication to build confidence in an interpretation. Indeed, in the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP) study, it was the entire biomarker battery which went into defining the final characteristics of the experimental biomarkerdefined entities, which were called “psychosis biotypes”. These biotype constructs have provided research with an alternative to phenomenologically defined entities, as a stage in developing final disease cate gories. Moreover, it is the full biomarker battery which can be ap plied to distinguishing and understanding defined features of the illness, such as negative symptoms. BSNIP researchers have developed several individual studies, now ongoing, to test the clinical applicability of the above biotype constructs. One such study tests the hypothesis that biotype 1, with its low intrinsic EEG activity, is a biomarker which indicates responsiveness to clozapine; specifically, we test the hypothesis that increasing intrinsic EEG activity with clozapine in biotype 1 will correlate with symptomatological improvement, using the attractor network model. A second study, designed to predict treatment response in early psychosis, hypothesizes that the biotypes will define good (biotype 3), moderate (biotype 2) or poor (biotype 1) response to standard coordinated specialty care (CSC). In each of these examples, a doubleblind trial of the biomarker observation (now ongoing) is necessary, and its application can only be supported if this is done with rigorous design. There is no doubt that considerable hard work will have to go into the study of biomarkers in psychiatry before we are able to bring them to a clinically useful place. Yet, the validation of biomarkers, as reviewed in AbiDargham et al’s paper, can be so decisive for the future of our field that these stud ies need to be conducted. Costs have to be born. Yes, wisely; but urgently.","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"271-272"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168170/pdf/WPS-22-271.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
World Psychiatry 22:2 June 2023 ophrenia and comorbid cannabis use disorder. This finding highlights the malleable nature of biological markers in the context of highly prevalent comorbidities (i.e., substance use disorders) which cooccur not only with schizophrenia but also with several other neurodevelopmental and mental disorders. Altogether, the insights from the AbiDargham et al’s review and the advances, limitations and opportunities discussed here suggest that, along with the excitement that novel approaches and technologies will likely bring to the biomarker discovery field, we need to remain mindful of the inherent challenges, particularly the biopsychosocial nature of psychiatric disorders and the multiple sources of interand intraindividual variability influencing clinical outcomes. We also need to work towards research endeavours that are better poised to address these challenges via collaboration between biological and psychosocial scientists, concerted largescale international efforts to improve and harmonize both biological and behavioural measures (as well as their underpinning ontologies), and incorporation of people’s living experiences into our definitions and measurements of biomarkers.
{"title":"Discovering informative biomarkers in psychiatry.","authors":"Carol A Tamminga","doi":"10.1002/wps.21084","DOIUrl":"https://doi.org/10.1002/wps.21084","url":null,"abstract":"World Psychiatry 22:2 June 2023 ophrenia and comorbid cannabis use disorder. This finding highlights the malleable nature of biological markers in the context of highly prevalent comorbidities (i.e., substance use disorders) which cooccur not only with schizophrenia but also with several other neurodevelopmental and mental disorders. Altogether, the insights from the AbiDargham et al’s review and the advances, limitations and opportunities discussed here suggest that, along with the excitement that novel approaches and technologies will likely bring to the biomarker discovery field, we need to remain mindful of the inherent challenges, particularly the biopsychosocial nature of psychiatric disorders and the multiple sources of interand intraindividual variability influencing clinical outcomes. We also need to work towards research endeavours that are better poised to address these challenges via collaboration between biological and psychosocial scientists, concerted largescale international efforts to improve and harmonize both biological and behavioural measures (as well as their underpinning ontologies), and incorporation of people’s living experiences into our definitions and measurements of biomarkers.","PeriodicalId":23858,"journal":{"name":"World Psychiatry","volume":"22 2","pages":"270-271"},"PeriodicalIF":73.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168152/pdf/WPS-22-270.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9436371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：